JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease
(World News Science)

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease September 22, 2020 9:45am EDT Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA`s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced...